SCM
CHRS icon

Sterling Capital Management’s Coherus Oncology CHRS Stock Holding History

Sterling Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.39K Sell
2,595
-1,758
-40% -$3.12K ﹤0.01% 2785
2025
Q4 		$6.18K Sell
4,353
-672
-13% -$979 ﹤0.01% 2818
2025
Q3 		$8.24K Buy
5,025
+2,731
+119% +$3.04K ﹤0.01% 2593
2025
Q2 		$1.68K Buy
2,294
+787
+52% +$679 ﹤0.01% 2960
2025
Q1 		$1.22K Sell
1,507
-1,316
-47% -$1.51K ﹤0.01% 2751
2024
Q4 		$3.9K Buy
2,823
+2,535
+880% +$2.84K ﹤0.01% 2566
2024
Q3 		$300 Buy
+288
New +$395 ﹤0.01% 3033

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return